DNTH Company Profile and Key Details

DNTH has shown sold momentum, gaining 19.12% over the past week and 30.72% over the past quarter, though year-to-date performance is up 13.08%. Short-term trend indicators are bearishly aligned (SMA20 -2.27%, SMA50 8.86%, SMA200 55.32%). The stock’s 14-day RSI is 52.68 (neutral), while the ATR of 3.15 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -14.42% below its high and over 268.2% above its low. Average 10-day trading volume of 468.14 thousand shares is below the 3-month average of 754.81 thousand, indicating normal recent market interest.

Dianthus Therapeutics, Inc. has 39.82 million shares outstanding. The public float is 11.34 million shares, elevated short interest at 21.21% of float. This equals 5.58 million shares. The short ratio is 15.25 days. Institutional investors hold 133.49% of the float. Insiders own 7.86%. Fairmount Funds Management LLC holds 1.93 million shares, Randhawa Simrat has 4.00 thousand shares and Savitz Ryan has 0.00 shares. Over the past six months, insider transactions show net selling. They sold 167.61 thousand shares across 4 transactions.

Dianthus Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$6.80. This means the shares are trading below this model’s fair value.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) closed at $49.72 USD, gaining $2.25 (4.74%) from the previous close of $47.47. The stock is currently mid-range between its 52-week high and low $13.37 and $57.50. With a market capitalization of about $1.80 billion, Dianthus Therapeutics, Inc. is classified as a small-cap and shows market-like volatility (beta ~1.23). Key stats such as the average daily volume over the past year has been around 771.05 thousand shares, in line with its 52-week average. Headquartered in New York City, NY, Dianthus Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Marino Garcia, the company employs approximately 78 people and listed since June 21, 2018. Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases.

Dianthus Therapeutics, Inc. generated EPS of -$3.49 over the past year. Five-year average earnings growth is 40.14%. Wall Street analysts project EPS growth of -18.86% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 8 Strong Buy ratings, 10 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $100.00 to $36.00. The high target offers 101.13% upside. The low target suggests -27.59% downside. The mean target is $59.72. This offers 20.11% upside. Dianthus Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 05, 2025, missed forecasts by 12.79%. The prior quarter beat by 2.33%. Over the last six quarters, Apple has recorded several small beats. These include 2.0% in August 08, 2024.

Our AI price prediction model suggests that Dianthus Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 5.67%, with price expected at $52.54 by March 04, 2026, within a range of $48.35 to $56.91 3-Month Outlook: Projected fall of -9.9%, reaching $44.80 by May 19, 2026, with a range of $43.28 to $46.72. 1-Year Outlook: Projected gain of 12.65%, with price at $56.01 by February 18, 2027, within a range of $53.62 to $58.21.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) shares are up 13.08% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Dianthus Therapeutics, Inc. trading at a premium to the broader market with a P/E of -14.52. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $58.14, suggesting 16.93% upside. Our AI forecast model points to short-term strength (5.67% over two weeks), a medium-term fall (-9.9% over three months), and a longer-term gain (12.65% over one year), with expected trading ranges indicating moderate volatility.

Dianthus Therapeutics, Inc. trades at a P/E ratio of -14.52, slightly below the S&P 500 average, with a price-to-sales ratio of 571.2 and a price-to-book ratio of 3.36 trading at moderately above to book value. The P/FCF stands at -16.04, also below market averages.